查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1580875

肌张力障碍治疗药物市场：按药物类型、给药方法、最终用户划分 - 全球预测 2025-2030

Dystonia Drugs Market by Drug Type (Anticholinergic Drugs, Botulinum Toxins, Dopaminergic Drugs), Mode of Administration (Injectable, Oral), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肌张力障碍治疗药物市场价值为8.0617亿美元，预计到2024年将达到8.5148亿美元，复合年增长率为5.81%，到2030年将达到11.9716亿美元。

肌张力障碍治疗市场包括旨在治疗肌张力失调的药物和治疗性介入，肌张力失调是一种运动障碍，其特征是不自主的肌肉收缩，导致重复运动和异常姿势。肌张力障碍治疗药物的需求源于肌肌张力不全症对患者生活品质的重大影响，这需要有效的治疗来缓解症状。这些药物用于治疗成人和儿童患者的各种肌张力不全症，包括颈部肌肌张力不全症、眼睑痉挛和整体肌张力不全症。最终用途范围包括医院、专科诊所和居家照护机构等医疗保健提供者。

主要市场统计
基准年[2023] 80617万美元
预测年份 [2024] 85148万美元
预测年份 [2030] 11.9716亿美元
复合年增长率（%） 5.81%

影响市场的主要成长要素包括肌张力不全症盛行率的增加、对神经系统疾病理解的重大发展以及新疗法的开发。尤其是生技药品和肉毒桿菌毒素，因其在控制症状、同时最大限度地减少副作用方面的有效性和精确性而越来越受欢迎。新的商机存在于生物技术领域，该领域正在创新针对肌张力不全症病理学分子层面的基因疗法和精准医学方法。生技公司和学术机构之间的策略联盟可以带来重大进展。

然而，市场成长面临着治疗成本高、一般医疗保健提供者缺乏理解以及严格的法规环境等挑战。此外，某些治疗方法，例如肉毒桿菌毒素，需要高度专业化的管理，需要培训和专业知识，而这些培训和专业知识并不总是容易获得，特别是在发展中地区。

创新和研究的机会包括开发针对肌张力不全症特定神经途径的小分子，以及使用人工智慧来实现更好的诊断和个人化治疗计划。此外，对非药物干预措施（例如深部脑部刺激和物理治疗）的研究可以补充药物治疗并提供整体治疗选择。

了解肌张力障碍治疗药物市场作为更广泛的神经系统疾病治疗中的利基市场的微妙本质对于获得市场占有率和预测未来趋势至关重要。公司应专注于医疗保健提供者的教育和意识计划，以更好地向从业者介绍肌张力障碍治疗，并让先进的治疗选择更广泛地提供。

市场动态：揭示快速发展的肌张力障碍治疗市场的关键市场洞察

供需的动态交互作用正在改变肌张力障碍治疗药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 运动障碍的盛行率不断上升，导致全球对肌张力障碍治疗药物的需求增加
    • 医学研究和生物技术的不断进步影响肌张力障碍治疗选择
    • 医疗保健支出的增加和可近性的改善推动了肌张力障碍治疗药物的需求
    • 提高患者认识并改善诊断技术以提高肌张力不全症的早期诊断率
  • 市场限制因素
    • 严格的监管要求影响肌张力障碍治疗的核准流程
    • 缺乏认识和正确诊断限制了肌张力不全症患者的有效治疗
  • 市场机会
    • 针对肌张力不全症的根本原因开发新的治疗药物
    • 透过将个人化医疗整合到肌张力障碍治疗中来改善患者的治疗效果
    • 扩大新兴市场的医疗基础设施为肌张力障碍治疗药物製造商创造了新的机会
  • 市场挑战
    • 严格的监管要求和核准流程阻碍了新的肌张力障碍治疗的推出
    • 肌张力不全症失调罕见导致的临床试验挑战影响药物开发效率

波特的五力：驾驭肌张力障碍治疗药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肌张力障碍治疗市场的外在影响

外在宏观环境因素在塑造肌张力障碍治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肌张力障碍治疗药物市场的竞争状况

对肌张力障碍治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肌肌张力障碍治疗市场供应商的绩效评估

FPNV 定位矩阵是评估肌张力障碍治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製肌张力障碍治疗药物市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对肌张力障碍治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 运动障碍的日益流行正在推动全球肌张力障碍治疗的需求
      • 医学研究和生物技术的进步影响肌张力不全症的治疗选择
      • 医疗成本的上升和获取的便利性推动了肌张力障碍治疗药物的需求
      • 提高患者意识提升和诊断技术将改善肌张力不全症的早期诊断
    • 抑制因素
      • 严格的监管要求影响肌张力障碍治疗的核准流程
      • 缺乏认识和正确诊断限制了肌张力不全症患者的有效治疗
    • 机会
      • 开发针对肌张力不全症根本原因的新治疗药物
      • 透过将个人化医疗方法整合到肌张力障碍治疗中来改善患者的治疗效果
      • 扩大新兴市场的医疗保健基础设施为肌张力障碍治疗药物製造商创造了新的机会
    • 任务
      • 严格的监管要求和核准流程阻碍了肌张力不全症新治疗方法的推出
      • 肌张力不全症失调罕见导致的临床试验挑战影响药物开发效率
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肌张力障碍治疗药物市场（依药物类型）

  • 抗胆碱能药物
  • 肉毒桿菌毒素
  • 多巴胺促效剂
  • 肌肉鬆弛剂

第七章依管理方式肌张力障碍治疗药物市场

  • 可注射的
  • 口服

第八章肌张力障碍治疗药物市场：依最终使用者分类

  • 诊所
  • 家庭护理设置
  • 医院

第九章 北美和南美肌肌张力障碍治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区肌张力障碍治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲肌张力障碍治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Evolus, Inc.
  • Galderma SA
  • GlaxoSmithKline PLC
  • Ipsen Biopharmaceuticals, Inc.
  • Medytox
  • Novartis AG
  • Revance Therapeutics, Inc.
  • Sanofi SA
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • Uniprix
Product Code: MRR-92533CCD3ABC

The Dystonia Drugs Market was valued at USD 806.17 million in 2023, expected to reach USD 851.48 million in 2024, and is projected to grow at a CAGR of 5.81%, to USD 1,197.16 million by 2030.

The dystonia drugs market encompasses the pharmaceutical products and therapeutic interventions designed to treat dystonia, a movement disorder characterized by involuntary muscle contractions that cause repetitive movements or abnormal postures. The necessity for dystonia drugs stems from the significant impact of the disorder on patients' quality of life, necessitating effective management to alleviate symptoms. Applications of these drugs span across various forms of dystonia, including cervical dystonia, blepharospasm, and general dystonia, targeting both adults and pediatric patients. End-use scope includes healthcare providers such as hospitals, specialty clinics, and homecare settings.

KEY MARKET STATISTICS
Base Year [2023] USD 806.17 million
Estimated Year [2024] USD 851.48 million
Forecast Year [2030] USD 1,197.16 million
CAGR (%) 5.81%

Key growth factors influencing the market include increasing prevalence of dystonia, advancements in neurological disorder understanding, and development of novel therapeutics. Biologics and botulinum toxins are particularly gaining traction due to their efficacy and precision in managing symptoms with minimal side effects. Emerging opportunities lie in the biotechnology sector, which is innovating gene therapies and precision medicine approaches aimed at the molecular level of dystonia pathology. Strategic partnerships between biotech firms and academic institutions could yield significant advancements.

However, market growth faces challenges such as high treatment costs, limited understanding among general healthcare providers, and stringent regulatory environments. Additionally, the need for highly specialized administration of certain therapies like botulinum toxins necessitates training and expertise that aren't always readily available, particularly in developing regions.

Opportunities for innovation and research include the development of small molecules targeting specific neurological pathways involved in dystonia, and leveraging artificial intelligence for better diagnosis and personalized treatment plans. Furthermore, research into non-pharmacological interventions, such as deep brain stimulation and physical therapies, can complement drug therapies and provide holistic treatment options.

Understanding the nuanced nature of the dystonia drugs market as a niche within the broader neurological disorder therapy landscape is crucial for capturing market share and anticipating future trends. Companies should focus on educating healthcare providers and investing in awareness programs to better inform practitioners about dystonia treatments and foster wider adoption of advanced therapeutic options.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dystonia Drugs Market

The Dystonia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of movement disorders leading to higher demand for dystonia drugs worldwide
    • Rising advancements in medical research and biotechnology impacting dystonia treatment options
    • Growing healthcare expenditure and accessibility driving the demand for dystonia therapeutics
    • Enhanced patient awareness and improved diagnostic techniques boosting early dystonia diagnosis rates
  • Market Restraints
    • Stringent regulatory requirements affecting the approval process for dystonia drugs
    • Lack of awareness and proper diagnosis limiting the effective treatment of dystonia patients
  • Market Opportunities
    • Development of novel therapeutic agents targeting underlying causes of dystonia
    • Integration of personalized medicine approaches for dystonia treatment to improve patient outcomes
    • Expansion of healthcare infrastructure in emerging markets creating new opportunities for dystonia drug manufacturers
  • Market Challenges
    • Stringent regulatory requirements and approval processes hindering the introduction of new dystonia treatments
    • Challenges in clinical trials due to the rarity of dystonia affecting drug development efficiency

Porter's Five Forces: A Strategic Tool for Navigating the Dystonia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dystonia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dystonia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dystonia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dystonia Drugs Market

A detailed market share analysis in the Dystonia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dystonia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dystonia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dystonia Drugs Market

A strategic analysis of the Dystonia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dystonia Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Cipla Limited, Dr. Reddy's Laboratories, Evolus, Inc., Galderma SA, GlaxoSmithKline PLC, Ipsen Biopharmaceuticals, Inc., Medytox, Novartis AG, Revance Therapeutics, Inc., Sanofi S.A., Sihuan Pharmaceutical Holdings Group Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, and Uniprix.

Market Segmentation & Coverage

This research report categorizes the Dystonia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anticholinergic Drugs, Botulinum Toxins, Dopaminergic Drugs, and Muscle Relaxants.
  • Based on Mode of Administration, market is studied across Injectable and Oral.
  • Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of movement disorders leading to higher demand for dystonia drugs worldwide
      • 5.1.1.2. Rising advancements in medical research and biotechnology impacting dystonia treatment options
      • 5.1.1.3. Growing healthcare expenditure and accessibility driving the demand for dystonia therapeutics
      • 5.1.1.4. Enhanced patient awareness and improved diagnostic techniques boosting early dystonia diagnosis rates
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements affecting the approval process for dystonia drugs
      • 5.1.2.2. Lack of awareness and proper diagnosis limiting the effective treatment of dystonia patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel therapeutic agents targeting underlying causes of dystonia
      • 5.1.3.2. Integration of personalized medicine approaches for dystonia treatment to improve patient outcomes
      • 5.1.3.3. Expansion of healthcare infrastructure in emerging markets creating new opportunities for dystonia drug manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval processes hindering the introduction of new dystonia treatments
      • 5.1.4.2. Challenges in clinical trials due to the rarity of dystonia affecting drug development efficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dystonia Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anticholinergic Drugs
  • 6.3. Botulinum Toxins
  • 6.4. Dopaminergic Drugs
  • 6.5. Muscle Relaxants

7. Dystonia Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Dystonia Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals

9. Americas Dystonia Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Dystonia Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Dystonia Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Cipla Limited
  • 3. Dr. Reddy's Laboratories
  • 4. Evolus, Inc.
  • 5. Galderma SA
  • 6. GlaxoSmithKline PLC
  • 7. Ipsen Biopharmaceuticals, Inc.
  • 8. Medytox
  • 9. Novartis AG
  • 10. Revance Therapeutics, Inc.
  • 11. Sanofi S.A.
  • 12. Sihuan Pharmaceutical Holdings Group Ltd.
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Limited
  • 15. Uniprix

LIST OF FIGURES

  • FIGURE 1. DYSTONIA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DYSTONIA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSTONIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DYSTONIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DYSTONIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSTONIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSTONIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DYSTONIA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY ANTICHOLINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY BOTULINUM TOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY DOPAMINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DYSTONIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DYSTONIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DYSTONIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DYSTONIA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. DYSTONIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. DYSTONIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023